Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders
Organophosphate compounds (OPs) interfere with neurodevelopment and are neurotoxic for humans and animals. They are first biotransformed to the more toxic oxon form, and then hydrolyzed to specific metabolites by the enzyme paraoxonase/arylesterase, encoded by the gene <i>PON1</i> locate...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/2/164 |
| _version_ | 1797408257702100992 |
|---|---|
| author | Ignazio Stefano Piras Stefano Gabriele Laura Altieri Federica Lombardi Roberto Sacco Carla Lintas Barbara Manzi Paolo Curatolo Maria Nobile Catia Rigoletto Massimo Molteni Antonio M. Persico |
| author_facet | Ignazio Stefano Piras Stefano Gabriele Laura Altieri Federica Lombardi Roberto Sacco Carla Lintas Barbara Manzi Paolo Curatolo Maria Nobile Catia Rigoletto Massimo Molteni Antonio M. Persico |
| author_sort | Ignazio Stefano Piras |
| collection | DOAJ |
| description | Organophosphate compounds (OPs) interfere with neurodevelopment and are neurotoxic for humans and animals. They are first biotransformed to the more toxic oxon form, and then hydrolyzed to specific metabolites by the enzyme paraoxonase/arylesterase, encoded by the gene <i>PON1</i> located on human chr. 7q21.3. In autism spectrum disorder (ASD) and in attention-deficit/hyperactivity disorder (ADHD), a correlation between OP exposure and disease onset has been reported. In this case-control study, we aimed to replicate our previous work showing reduced levels of serum PON1 arylesterase activity in Italian and Caucasian-American ASD samples, and to extend our analysis to other neurodevelopmental disorders, namely ADHD and developmental language disorder (DLD), also known as specific language impairment (SLI). The arylesterase activity, measured using standard spectrophotometric methods, is significantly reduced in the ADHD, and not in the ASD sample compared with the controls. Our previous results seemingly stem from spuriously high arylesterase levels in the former control sample. Finally, genotyping SNPs rs705379 and rs662 using TDI-FP, a significant effect of rs705379 alleles on the serum arylesterase activity is observed in all of the subgroups tested, regardless of diagnosis, as well as a lack of association between <i>PON1</i> gene polymorphisms and ASD/ADHD susceptibility in the Italian population. In summary, the serum arylesterase activity is reduced in children and adolescents with ADHD, and this reduction is not due to the functional <i>PON1</i> gene variants assessed in this study. Based on previous literature, it may more likely reflect enhanced oxidative stress than specific genetic underpinnings. |
| first_indexed | 2024-03-09T03:56:45Z |
| format | Article |
| id | doaj.art-a89c555d26e948cda00d25cc88e6a03b |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-09T03:56:45Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-a89c555d26e948cda00d25cc88e6a03b2023-12-03T14:20:06ZengMDPI AGAntioxidants2076-39212021-01-0110216410.3390/antiox10020164Reevaluation of Serum Arylesterase Activity in Neurodevelopmental DisordersIgnazio Stefano Piras0Stefano Gabriele1Laura Altieri2Federica Lombardi3Roberto Sacco4Carla Lintas5Barbara Manzi6Paolo Curatolo7Maria Nobile8Catia Rigoletto9Massimo Molteni10Antonio M. Persico11Unit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, ItalyUnit of Child and Adolescent Neuropsychiatry, University of Rome “Tor Vergata”, I-00133 Rome, ItalyUnit of Child and Adolescent Neuropsychiatry, University of Rome “Tor Vergata”, I-00133 Rome, ItalyChild Psychopathology Unit, Scientific Institute, IRCCS ‘E. Medea’, I-23842 Bosisio Parini (LC), ItalyChild Psychopathology Unit, Scientific Institute, IRCCS ‘E. Medea’, I-23842 Bosisio Parini (LC), ItalyChild Psychopathology Unit, Scientific Institute, IRCCS ‘E. Medea’, I-23842 Bosisio Parini (LC), ItalyInterdepartmental Program “Autism 0–90”, “G. Martino” University Hospital, University of Messina, I-98122 Messina, ItalyOrganophosphate compounds (OPs) interfere with neurodevelopment and are neurotoxic for humans and animals. They are first biotransformed to the more toxic oxon form, and then hydrolyzed to specific metabolites by the enzyme paraoxonase/arylesterase, encoded by the gene <i>PON1</i> located on human chr. 7q21.3. In autism spectrum disorder (ASD) and in attention-deficit/hyperactivity disorder (ADHD), a correlation between OP exposure and disease onset has been reported. In this case-control study, we aimed to replicate our previous work showing reduced levels of serum PON1 arylesterase activity in Italian and Caucasian-American ASD samples, and to extend our analysis to other neurodevelopmental disorders, namely ADHD and developmental language disorder (DLD), also known as specific language impairment (SLI). The arylesterase activity, measured using standard spectrophotometric methods, is significantly reduced in the ADHD, and not in the ASD sample compared with the controls. Our previous results seemingly stem from spuriously high arylesterase levels in the former control sample. Finally, genotyping SNPs rs705379 and rs662 using TDI-FP, a significant effect of rs705379 alleles on the serum arylesterase activity is observed in all of the subgroups tested, regardless of diagnosis, as well as a lack of association between <i>PON1</i> gene polymorphisms and ASD/ADHD susceptibility in the Italian population. In summary, the serum arylesterase activity is reduced in children and adolescents with ADHD, and this reduction is not due to the functional <i>PON1</i> gene variants assessed in this study. Based on previous literature, it may more likely reflect enhanced oxidative stress than specific genetic underpinnings.https://www.mdpi.com/2076-3921/10/2/164arylesteraseattention deficit/hyperactivity disorder (ADHD)autismautism spectrum disorderdevelopmental language disorderorganophosphate |
| spellingShingle | Ignazio Stefano Piras Stefano Gabriele Laura Altieri Federica Lombardi Roberto Sacco Carla Lintas Barbara Manzi Paolo Curatolo Maria Nobile Catia Rigoletto Massimo Molteni Antonio M. Persico Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders Antioxidants arylesterase attention deficit/hyperactivity disorder (ADHD) autism autism spectrum disorder developmental language disorder organophosphate |
| title | Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders |
| title_full | Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders |
| title_fullStr | Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders |
| title_full_unstemmed | Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders |
| title_short | Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders |
| title_sort | reevaluation of serum arylesterase activity in neurodevelopmental disorders |
| topic | arylesterase attention deficit/hyperactivity disorder (ADHD) autism autism spectrum disorder developmental language disorder organophosphate |
| url | https://www.mdpi.com/2076-3921/10/2/164 |
| work_keys_str_mv | AT ignaziostefanopiras reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT stefanogabriele reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT lauraaltieri reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT federicalombardi reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT robertosacco reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT carlalintas reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT barbaramanzi reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT paolocuratolo reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT marianobile reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT catiarigoletto reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT massimomolteni reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders AT antoniompersico reevaluationofserumarylesteraseactivityinneurodevelopmentaldisorders |